Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
128
COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt
Microbial eradication
Time frame: 10 days
Mortality
Time frame: 30 days
Nephrotoxicity
Time frame: 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.